Lifeward Ltd. announced the U.S. national launch of its ReWalk 7 Personal Exoskeleton on April 15, 2025. This marks the commercial availability of the seventh generation of its personal exoskeleton technology for individuals with spinal cord injury (SCI).
The ReWalk 7 incorporates new and enhanced features, including cloud connectivity and customizable walking speeds, designed to provide a more functional and personalized walking experience. The device aims to optimize real-world use and enhance user confidence and control.
This launch follows the ReWalk 7's FDA clearance in March 2025. It also builds on the 2024 establishment of a Medicare reimbursement pathway for personal exoskeleton use, which expanded access for individuals living with SCI.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.